The Institute for Clinical and Economic Review on Wednesday published an evidence report on the comparative clinical effectiveness and value of three inhibitors used in ovarian cancer treatments.
“PARP inhibitors have the potential to improve upon existing treatment paradigms for women who currently have limited therapeutic options,” ICER’s Chief Scientific Officer Dan Ollendorf said. “Differences in study design and measurement prevented us from making any explicit comparisons between these drugs.”
Click here to read the full press release on ICER’s website.
